The Phase Ib/II trial of copanlisib in combination with trastuzumab targets a niche market of pretreated recurrent or metastatic HER2-positive breast cancer patients. Given the limited treatment options for this patient population, successful outcomes could position this combination therapy as a valuable addition to existing HER2-targeted therapies. The competitive landscape includes other HER2-targeted therapies and PI3K inhibitors, necessitating a focus on demonstrating superior efficacy and safety profiles. The completion of this trial may enhance the market positioning of Cancer Trials Ireland and potential partnerships with larger pharmaceutical entities for further development and commercialization.